| Name | 2-[(3S)-6-[[3-[2,6-dimethyl-4-(3-methylsulfonylpropoxy)phenyl]phenyl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid,hydrate |
|---|---|
| Synonyms |
Fasiglifam hemihydrate
TAK875 hemihydrate TAK-875 hymihydrate UNII-8LDT91CH8A 3-Benzofuranacetic acid,6-((2',6'-dimethyl-4'-(3-(methylsulfonyl)propoxy)(1,1'-biphenyl)-3-yl)methoxy)-2,3-dihydro-,hydrate (2:1),(3S) (3S)-6-((2',6'-Dimethyl-4'-(3-(methylsulfonyl)propoxy) biphenyl-3-yl)methoxy)-2,3-dihydro-l-benzofuran-3-yl)acetic acid hemihydrate TAK-875(0.5H2O) Fasiglifam(TAK-875) Hemihydrate ,S2637 TAK875 [(3S)-6-({2',6'-dimethyl-4'-[3-(methylsulfonyl)propoxy]biphe-nyl-3-yl}meth-oxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid hemi-hydrate (3S)-6-[[2',6'-Dimethyl-4'-[3-(methylsulfonyl)propoxy][1,1'-biphenyl]-3-yl]methoxy]-2,3-dihydro-3-benzofuranacetic acid hydrate (2:1) Fasiglifam(TAK-875) Hemihydrate TAK875 (3S)-6-[[2',6'-Dimethyl-4'-[3-(methylsulfonyl)propoxy][1,1'-biphenyl]-3-yl]methoxy]-2,3-dihydro-3-benzofuranacetic acid (3S)-6-((2',6'-Dimethyl-4'-(3-(methylsulfonyl)propoxy) biphenyl-3-yl)methoxy)-2,3-dihydro-l-benzofuran-3-yl)acetic acid hydrate TAK-875(b) |
| Description | Fasiglifam (TAK-875) hemihydrate is a potent, selective and orally active GPR40 agonist with EC50 of 72 nM. Fasiglifam enhances glucose-dependent insulin secretion and improves hyperglycemia in type 2 diabetic rats. Fasiglifam can induce liver injury[1][2][3][4]. |
|---|---|
| Related Catalog | |
| Target |
EC50: 72 nM (GPR40)[1] |
| References |
| Molecular Formula | C58H66O15S2 |
|---|---|
| Molecular Weight | 1067.3 |
| Exact Mass | 1066.38431374 |
| PSA | 224.25000 |
| LogP | 12.72450 |
| Storage condition | -20℃ |